Dermata Therapeutics, Inc. $DRMA

By Microcap Ledger desk · CIK 0001853816

Facts as of Oct 11, 2026, 08:18 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: San Diego, CA
Fiscal year end: December 31
Shares outstanding: 4,022,143 [10-Q 2026-08-11]
as of 2026-08-10

Sources: [10-K 2026-03-26]

What the company doesAI summary of filing

Dermata Therapeutics is a pre-revenue clinical-stage company that recently pivoted from developing prescription acne treatments to creating direct-to-consumer and business-to-business skincare products. The company is developing cosmetic and over-the-counter skincare products built around its proprietary Bioneedle ingredient, derived from Spongilla lacustris, a freshwater sponge. Dermata plans to launch its first commercial product, the Tome Foundational Treatment, in mid-2026, followed by a Clearing Treatment for acne, and is also exploring use of its Bioneedle technology for delivering macromolecules like botulinum toxin to treat aesthetic and medical skin conditions. [10-K 2026-03-26]

Segments: Tome Foundational Treatment, Tome Clearing Treatment, Bioneedle Delivery System, Future OTC and Cosmetic Products

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$4.81M	−$4.90M	$4.41M	[10-Q 2026-08-11]
FY ended Dec 2025	—	−$7.56M	−$7.80M	$7.52M	[10-K 2026-03-26]
FY ended Dec 2024	—	−$12.29M	−$11.16M	$3.16M	[10-K 2026-03-26]

Quarterly cash burn: −$2.45M
Cash runway Estimate: ~5.4 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-12	2,040,768	[10-Q 2024-11-13]
2025-03-11	5,430,648	[10-K 2025-03-17]
2025-05-12	6,378,118	[10-Q 2025-05-14]
2025-08-11	681,557	[10-Q 2025-08-13]
2025-11-12	1,026,457	[10-Q 2025-11-14]
2026-03-25	4,022,143	[10-K 2026-03-26]
2026-05-12	4,022,143	[10-Q 2026-05-13]
2026-08-10	4,022,143	[10-Q 2026-08-11]

Shelf registration: S-3 filed 2026-10-09; no effectiveness notice found in EDGAR [S-3 2026-10-09]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-07-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-07-07	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-07-07]
2025-05-16	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-05-16]
2025-03-25	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-03-25]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-08-16	Proehl Gerald T	grant	170,068	—	[4 2026-08-18]
2026-08-16	Van Hoose Kyri K.	grant	102,040	—	[4 2026-08-18]
2026-06-16	Scott Kathleen D.	sell	11	$1.19	[4 2026-06-16]
2026-02-17	Bedoya-Toro Munera Maria E	buy	1,000	$1.27	[4 2026-03-17]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-09	S-3	Registration statement
2026-08-17	8-K	Material agreement entered; Unregistered sale of equity; Other events
2026-08-11	10-Q	Quarterly report
2026-08-11	8-K	Results of operations
2026-08-05	8-K	Other events
2026-06-01	13D	Beneficial ownership report (5%+ holder)
2026-05-29	424B3	Prospectus or prospectus supplement
2026-05-27	8-K	Director or officer change; Shareholder vote results
2026-05-22	S-3/A	Registration statement
2026-05-13	13G/A	Beneficial ownership report (5%+ holder)
2026-05-13	10-Q	Quarterly report
2026-05-13	8-K	Results of operations

Facts as of Oct 11, 2026, 08:18 AM UTC. Small caps move fast; check the latest filings.